Yongyue Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yongyue Wei has a total of 516 co-authors. Here are the top co-authors by number of shared publications:
- Feng Chen
Central Laboratory, Peking University School of Stomatology, Beijing 100081, China
25 shared publications David C. Christiani
Department of Environmental Health Harvard T.H Chan School of Public Health 02115 Boston MA USA
15 shared publications- Ruyang Zhang
Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
15 shared publications Feng Chen
School of Public Health, Nanjing Medical University , Nanjing 211166
14 shared publicationsLi Su
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, USA
13 shared publicationsRuyang Zhang
Department of Biostatistics, School of Public Health, Nanjing Medical University 1
13 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (10) , e70326
Bidirectional Synergistic Interaction Between Influenza Virus and SARS‐CoV‐2 in the Postpandemic Era: A Modeling Study
Introduction: Influenza and COVID‐19 are major respiratory diseases whose co‐circulation dynamics are not fully understood. Surveillance data from the postpandemic period, free from the confounding effects of nonpharmaceutical interventions (NPIs), provide a unique opportunity to study their interactions. This study aimed to (1) estimate the direction and strength of the epidemiological interactions between influenza virus and SARS‐CoV‐2 and (2) quantify the impact of these interactions on the cumulative disease burden. Methods: We developed a deterministic influenza virus × SARS‐CoV‐2 12‐compartmental model SIR × SEIR using weekly laboratory surveillance data from Hong Kong between 2023 and 2025. Interaction parameters were introduced across multiple pathways to quantify the effect of one virus on the transmission of the other. Model parameters were estimated via maximum likelihood estimation (MLE), with uncertainty assessed using bootstrap resampling. Counterfactual simulations were conducted to evaluate the impact of interactions on cumulative infection incidence. Sensitivity analyses were performed to evaluate the robustness of our findings. Results: The model identified a significant bidirectional synergistic interaction. Specifically, prior exposure to SARS‐CoV‐2 was associated with a relative risk of influenza virus infection that was 1.24 (95% CI: 1.13, 1.35) times higher compared to the scenario without interaction, while SARS‐CoV‐2 infection and recovery from it were associated with relative risks of influenza virus infection that were 2.43 (2.20, 2.66) and 12.04 (10.93, 13.17) times higher, respectively. Additionally, influenza virus infection was associated with a relative risk of SARS‐CoV‐2 infection that was 2.39 (2.17, 2.62) times higher, and recovery from influenza was associated with a relative risk of SARS‐CoV‐2 infection that was 9.92 (9.00, 10.84) times higher. Counterfactual analysis demonstrated that this interaction substantially amplified epidemic sizes. Conclusions: This study provides strong epidemiological evidence that influenza virus and SARS‐CoV‐2 exhibit a bidirectional synergistic interaction at the population level, which significantly elevates the total disease burden. These findings underscore the urgent need for multifaceted public health preparedness, including enhanced clinical management and multiplex testing, optimized vaccination strategies, and integrated multipathogen surveillance to mitigate the amplified burden from influenza virus‐SARS‐CoV‐2 synergy.
- 12 October 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (10) , e70326
Open AccessBidirectional Synergistic Interaction Between Influenza Virus and SARS‐CoV‐2 in the Postpandemic Era: A Modeling Study
Introduction: Influenza and COVID‐19 are major respiratory diseases whose co‐circulation dynamics are not fully understood. Surveillance data from the postpandemic period, free from the confounding effects of nonpharmaceutical interventions (NPIs), provide a unique opportunity to study their interactions. This study aimed to (1) estimate the direction and strength of the epidemiological interactions between influenza virus and SARS‐CoV‐2 and (2) quantify the impact of these interactions on the cumulative disease burden. Methods: We developed a deterministic influenza virus × SARS‐CoV‐2 12‐compartmental model SIR × SEIR using weekly laboratory surveillance data from Hong Kong between 2023 and 2025. Interaction parameters were introduced across multiple pathways to quantify the effect of one virus on the transmission of the other. Model parameters were estimated via maximum likelihood estimation (MLE), with uncertainty assessed using bootstrap resampling. Counterfactual simulations were conducted to evaluate the impact of interactions on cumulative infection incidence. Sensitivity analyses were performed to evaluate the robustness of our findings. Results: The model identified a significant bidirectional synergistic interaction. Specifically, prior exposure to SARS‐CoV‐2 was associated with a relative risk of influenza virus infection that was 1.24 (95% CI: 1.13, 1.35) times higher compared to the scenario without interaction, while SARS‐CoV‐2 infection and recovery from it were associated with relative risks of influenza virus infection that were 2.43 (2.20, 2.66) and 12.04 (10.93, 13.17) times higher, respectively. Additionally, influenza virus infection was associated with a relative risk of SARS‐CoV‐2 infection that was 2.39 (2.17, 2.62) times higher, and recovery from influenza was associated with a relative risk of SARS‐CoV‐2 infection that was 9.92 (9.00, 10.84) times higher. Counterfactual analysis demonstrated that this interaction substantially amplified epidemic sizes. Conclusions: This study provides strong epidemiological evidence that influenza virus and SARS‐CoV‐2 exhibit a bidirectional synergistic interaction at the population level, which significantly elevates the total disease burden. These findings underscore the urgent need for multifaceted public health preparedness, including enhanced clinical management and multiplex testing, optimized vaccination strategies, and integrated multipathogen surveillance to mitigate the amplified burden from influenza virus‐SARS‐CoV‐2 synergy.
- Open Access
- 2 September 2026
- Published by Elsevier in JACC: Asia
Spatiotemporal Analysis of Acute Aortic Syndrome in Jiangsu, China From Medical Record Front Page Registry
- 2 September 2026
- Published by Elsevier in JACC: Asia
Open AccessSpatiotemporal Analysis of Acute Aortic Syndrome in Jiangsu, China From Medical Record Front Page Registry
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Coronary computed tomography angiography to guide lipid management in an asymptomatic community-based population: RESPECT2 randomized controlled trial
Aims: Cardiovascular disease (CVD) risk assessment and risk-guided lipid management are cornerstones of primary prevention of atherosclerotic coronary artery disease (ACAD). However, the 10-year CVD risk is often limited by individual-level inaccuracy and poor adherence. This trial aimed to determine whether a coronary computed tomography angiography (CCTA)-guided strategy improves lipid management in asymptomatic populations. Methods and results: This pragmatic, open-label, assessor-blinded randomized trial was conducted in Nanjing, China. Asymptomatic community-dwelling adults aged 40–69 years with no history of CVD or prior use of lipid-lowering medication (LLM) were recruited. Participants were randomized to receive individualized LLM recommendations based either on CCTA findings (CCTA group) or on 10-year CVD risk (usual-care group). The primary outcome was the proportion of participants with regular LLM use (≥24 of preceding 30 days) at both the 6-month and 12-month follow-up visits. Of 3503 randomized participants, 3491 (1748 CCTA, 1743 usual-care) were included in the primary analysis (median [IQR] age, 55 [48–61] years; 60.2% women). Among 1516 participants undergoing CCTA, ACAD was detected in 565 (37.3%). The median follow-up was 12.5 months. Regular LLM use was higher in the CCTA group than in the usual-care group (12.5% [218/1748] vs. 8.1% [141/1743]; adjusted risk ratio, 1.57 [95% confidence interval, 1.29–1.91]; P < 0.001). During follow-up, invasive coronary procedures were more frequent in the CCTA group than in the usual-care group (29 procedures vs. 1). Conclusion: In asymptomatic populations, a CCTA-guided strategy modestly improved lipid management, though it increased invasive coronary procedures. Longer follow-up is needed to determine its effect on clinical events. Study Registration http://www.clinicaltrials.com; Identifier: NCT05725096.
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Coronary computed tomography angiography to guide lipid management in an asymptomatic community-based population: RESPECT2 randomized controlled trial
Aims: Cardiovascular disease (CVD) risk assessment and risk-guided lipid management are cornerstones of primary prevention of atherosclerotic coronary artery disease (ACAD). However, the 10-year CVD risk is often limited by individual-level inaccuracy and poor adherence. This trial aimed to determine whether a coronary computed tomography angiography (CCTA)-guided strategy improves lipid management in asymptomatic populations. Methods and results: This pragmatic, open-label, assessor-blinded randomized trial was conducted in Nanjing, China. Asymptomatic community-dwelling adults aged 40–69 years with no history of CVD or prior use of lipid-lowering medication (LLM) were recruited. Participants were randomized to receive individualized LLM recommendations based either on CCTA findings (CCTA group) or on 10-year CVD risk (usual-care group). The primary outcome was the proportion of participants with regular LLM use (≥24 of preceding 30 days) at both the 6-month and 12-month follow-up visits. Of 3503 randomized participants, 3491 (1748 CCTA, 1743 usual-care) were included in the primary analysis (median [IQR] age, 55 [48–61] years; 60.2% women). Among 1516 participants undergoing CCTA, ACAD was detected in 565 (37.3%). The median follow-up was 12.5 months. Regular LLM use was higher in the CCTA group than in the usual-care group (12.5% [218/1748] vs. 8.1% [141/1743]; adjusted risk ratio, 1.57 [95% confidence interval, 1.29–1.91]; P < 0.001). During follow-up, invasive coronary procedures were more frequent in the CCTA group than in the usual-care group (29 procedures vs. 1). Conclusion: In asymptomatic populations, a CCTA-guided strategy modestly improved lipid management, though it increased invasive coronary procedures. Longer follow-up is needed to determine its effect on clinical events. Study Registration http://www.clinicaltrials.com; Identifier: NCT05725096.
- Open Access
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1753280
Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, these therapies are associated with immune-related adverse events (irAEs), with thyroid dysfunction as one of the most common endocrine irAEs. The role of preexisting thyroid autoantibodies (Abs) in predicting endocrine irAEs and their impact on patient survival remains unclear. Objective: This study explored the relationship between preexisting thyroid antibodies and the development of endocrine irAEs, as well as their association with overall survival (OS) in patients treated with ICIs. Methods: We retrospectively reviewed patients with malignancy treated with one or more PD-(L)1 inhibitor between July 2018 and March 2022 at The First Affiliated Hospital of Nanjing Medical University, and 4,119 patients were initially included in this study. Ultimately, 585 patients whose anti-TPO and anti-Tg levels were measured before ICI treatment were analyzed. The patients were stratified based on their pre-existing thyroid antibody status. Multivariate Cox regression models were used to analyze the risk of thyroid irAEs and the differences in OS. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were employed to validate the robustness of the results. Results: Patients with pre-existing thyroid Ab (N = 80, 13.7%) had a significantly higher incidence of thyroid irAEs compared to the antibody-negative group (N = 505) (HR = 4.13, 95% CI: 2.69-6.35, p < 0.001). PSM and IPTW analyses further confirmed that patients with pre-existing thyroid Ab had a markedly increased risk of grade≥2 irAEs (HR = 7.54, 95% CI: 2.74-20.75, p < 0.001). No significant difference in OS was observed between the two groups (log-rank p = 0.5). Notably, patients with pre-existing thyroid Abs and irAEs had better survival outcomes (log-rank p = 0.027). A landmark analysis at 12 months indicated that patients who developed thyroid irAEs between 0 and 12 months of age had relatively low mortality rates over this time period. However, from 12 months onwards, the survival curves of the two groups tended to overlap. Conclusion: Preexisting thyroid antibodies provide a significant risk factor for thyroid irAEs in patients treated with ICIs. The development of thyroid irAEs has been associated with improved survival, thus suggesting a potential link between immune activation and clinical benefits.
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1753280
Open AccessClinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, these therapies are associated with immune-related adverse events (irAEs), with thyroid dysfunction as one of the most common endocrine irAEs. The role of preexisting thyroid autoantibodies (Abs) in predicting endocrine irAEs and their impact on patient survival remains unclear. Objective: This study explored the relationship between preexisting thyroid antibodies and the development of endocrine irAEs, as well as their association with overall survival (OS) in patients treated with ICIs. Methods: We retrospectively reviewed patients with malignancy treated with one or more PD-(L)1 inhibitor between July 2018 and March 2022 at The First Affiliated Hospital of Nanjing Medical University, and 4,119 patients were initially included in this study. Ultimately, 585 patients whose anti-TPO and anti-Tg levels were measured before ICI treatment were analyzed. The patients were stratified based on their pre-existing thyroid antibody status. Multivariate Cox regression models were used to analyze the risk of thyroid irAEs and the differences in OS. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were employed to validate the robustness of the results. Results: Patients with pre-existing thyroid Ab (N = 80, 13.7%) had a significantly higher incidence of thyroid irAEs compared to the antibody-negative group (N = 505) (HR = 4.13, 95% CI: 2.69-6.35, p < 0.001). PSM and IPTW analyses further confirmed that patients with pre-existing thyroid Ab had a markedly increased risk of grade≥2 irAEs (HR = 7.54, 95% CI: 2.74-20.75, p < 0.001). No significant difference in OS was observed between the two groups (log-rank p = 0.5). Notably, patients with pre-existing thyroid Abs and irAEs had better survival outcomes (log-rank p = 0.027). A landmark analysis at 12 months indicated that patients who developed thyroid irAEs between 0 and 12 months of age had relatively low mortality rates over this time period. However, from 12 months onwards, the survival curves of the two groups tended to overlap. Conclusion: Preexisting thyroid antibodies provide a significant risk factor for thyroid irAEs in patients treated with ICIs. The development of thyroid irAEs has been associated with improved survival, thus suggesting a potential link between immune activation and clinical benefits.
- Open Access
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (6) , 1115-1128
A trans-omics gene-smoking interaction study of lung cancer based on consortium data
Rationale: Genetically predicted molecular traits provide a cost-effective approach for identifying biomarkers and uncovering underlying biological mechanisms. We extended this framework to investigate gene-smoking interactions in lung cancer susceptibility. Objectives: To identify trans-omics gene-smoking interactions affecting lung cancer risk and to assess how biomarkers modify effect of smoking. Methods: We conducted the first trans-omics gene-smoking interaction study of lung cancer by integrating consortium-scale individual genotype data (27,737 cases vs 449,910 non-cases) from the International Lung Cancer OncoArray Consortium (ILCCO-OncoArray), Transdisciplinary Research Into Cancer of the Lung (TRICL), Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), and the UK Biobank (UKB) with alliance-based summary-level molecular quantitative trait loci (xQTL) data, involving DNA methylation, gene expression, protein, and metabolite. Based on the identified biomarkers, we developed a molecular modifying score (MMS) to delineate gene-smoking interaction patterns and stratify high-risk smokers of lung cancer. Measurements and Main Results: Eight biomarkers showing significant interactions with smoking were identified through a two-phase analytic strategy, comprising CpG sites in the nicotinic acetylcholine receptor region and gene RP11-326C3.14. The MMS, constructed by integrating these biomarkers with their effect estimates derived from meta-analysis of all available datasets, effectively stratified lung cancer risk among smokers. Trans-omics integrative analysis revealed functional relationships across molecular layers, particularly implicating the NELFE gene in smoking-related carcinogenesis pathways. Conclusions: The xWAS framework enables systematic discovery of trans-omics gene-environment interactions. The MMS effectively delineates the patterns of the interaction effects and facilitates risk stratification. Additionally, we launched a free online platform, LungCancer-xWAS-GxE (http://bigdata.njmu.edu.cn/LungCancer-xWAS-GxE/).
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (6) , 1115-1128
Open AccessA trans-omics gene-smoking interaction study of lung cancer based on consortium data
Rationale: Genetically predicted molecular traits provide a cost-effective approach for identifying biomarkers and uncovering underlying biological mechanisms. We extended this framework to investigate gene-smoking interactions in lung cancer susceptibility. Objectives: To identify trans-omics gene-smoking interactions affecting lung cancer risk and to assess how biomarkers modify effect of smoking. Methods: We conducted the first trans-omics gene-smoking interaction study of lung cancer by integrating consortium-scale individual genotype data (27,737 cases vs 449,910 non-cases) from the International Lung Cancer OncoArray Consortium (ILCCO-OncoArray), Transdisciplinary Research Into Cancer of the Lung (TRICL), Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), and the UK Biobank (UKB) with alliance-based summary-level molecular quantitative trait loci (xQTL) data, involving DNA methylation, gene expression, protein, and metabolite. Based on the identified biomarkers, we developed a molecular modifying score (MMS) to delineate gene-smoking interaction patterns and stratify high-risk smokers of lung cancer. Measurements and Main Results: Eight biomarkers showing significant interactions with smoking were identified through a two-phase analytic strategy, comprising CpG sites in the nicotinic acetylcholine receptor region and gene RP11-326C3.14. The MMS, constructed by integrating these biomarkers with their effect estimates derived from meta-analysis of all available datasets, effectively stratified lung cancer risk among smokers. Trans-omics integrative analysis revealed functional relationships across molecular layers, particularly implicating the NELFE gene in smoking-related carcinogenesis pathways. Conclusions: The xWAS framework enables systematic discovery of trans-omics gene-environment interactions. The MMS effectively delineates the patterns of the interaction effects and facilitates risk stratification. Additionally, we launched a free online platform, LungCancer-xWAS-GxE (http://bigdata.njmu.edu.cn/LungCancer-xWAS-GxE/).
- Open Access
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Medicine
- Vol. 4 (1) , 100195-1-100195-13
A global systematic analysis and statistical evaluation of prognostic prediction models for non-small cell lung cancer
Prognostic prediction models can aid clinical decision-making for high-risk non-small cell lung cancer (NSCLC) patients. We conducted a systematic search across multiple databases and evaluated eligible studies using PRISMA and PROBAST checklists. Of 28,833 references screened, 233 studies describing 268 models were included. Among them, 89 underwent external validation; 67 (75.28%) were classified with high risk for bias. Most models were developed in North America (45.06%). The median area under the receiver operating characteristic curve (AUC) for 1-, 3-, and 5-year predictions were 0.759, 0.720, and 0.691, respectively. The most common predictors were age (54.85%) and stage (58.21%). And, 47.01% of models were sex-specific. Recently, easily accessible radiomic features have been increasingly used in statistical modeling compared to molecular omics. Models integrating radiomic and clinical features showed potential for improved performance (1-, 3-, and 5-year AUCs: 0.931, 0.985, 0.942). Model discrimination varied across different studies, and there is a lack of model calibration and clinical utility. This review highlights advances and limitations in NSCLC prognostic models. To enhance model reliability and generalizability, it remains crucial to adhere to the TRIPOD guideline to perform prediction model study, and to emphasize comprehensive model validation and bias-reduction strategies. Following a step-by-step guide to develop and validate clinical prediction models by Efthimiou, et al. (BMJ, 2024), along with a multifaceted, multidisciplinary and multi-regional approach, is the key way to facilitate the development and clinical application of qualified models.
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Medicine
- Vol. 4 (1) , 100195-1-100195-13
Open AccessA global systematic analysis and statistical evaluation of prognostic prediction models for non-small cell lung cancer
Prognostic prediction models can aid clinical decision-making for high-risk non-small cell lung cancer (NSCLC) patients. We conducted a systematic search across multiple databases and evaluated eligible studies using PRISMA and PROBAST checklists. Of 28,833 references screened, 233 studies describing 268 models were included. Among them, 89 underwent external validation; 67 (75.28%) were classified with high risk for bias. Most models were developed in North America (45.06%). The median area under the receiver operating characteristic curve (AUC) for 1-, 3-, and 5-year predictions were 0.759, 0.720, and 0.691, respectively. The most common predictors were age (54.85%) and stage (58.21%). And, 47.01% of models were sex-specific. Recently, easily accessible radiomic features have been increasingly used in statistical modeling compared to molecular omics. Models integrating radiomic and clinical features showed potential for improved performance (1-, 3-, and 5-year AUCs: 0.931, 0.985, 0.942). Model discrimination varied across different studies, and there is a lack of model calibration and clinical utility. This review highlights advances and limitations in NSCLC prognostic models. To enhance model reliability and generalizability, it remains crucial to adhere to the TRIPOD guideline to perform prediction model study, and to emphasize comprehensive model validation and bias-reduction strategies. Following a step-by-step guide to develop and validate clinical prediction models by Efthimiou, et al. (BMJ, 2024), along with a multifaceted, multidisciplinary and multi-regional approach, is the key way to facilitate the development and clinical application of qualified models.
- Open Access
- 10 November 2025
- Published by Elsevier in Global Health Research and Policy
- Vol. 10 (1) , 1-5
The outbreak, response, and reflections on the chikungunya fever epidemic in Foshan City, China
- 10 November 2025
- Published by Elsevier in Global Health Research and Policy
- Vol. 10 (1) , 1-5
Open AccessThe outbreak, response, and reflections on the chikungunya fever epidemic in Foshan City, China
- Open Access
- 28 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Intravascular ultrasound–guided percutaneous coronary intervention in acute coronary syndrome stratified by the TVF-ACS risk score: the IVUS-ACS trial
Aims: The IVUS-ACS trial demonstrated that intravascular ultrasound (IVUS) guidance reduces target-vessel failure (TVF) in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Whether this benefit applies to all ACS patients across the spectrum of risk is unknown. We sought to develop a new risk score for 1-year TVF after PCI in ACS and determine whether IVUS guidance compared with angiography guidance improves outcomes in both high- and low-risk patients. Methods and results: From the angiography-guided group of the IVUS-ACS trial (n = 1743), the TVF-ACS risk score was developed using the least absolute shrinkage and selection operator method in a derivation group (n = 1288), and its robustness was assessed in an internal validation group (n = 455). External validation was then performed separately in the IVUS-XPL and ULTIMATE trials. Outcomes in high- and low-risk patients randomized to IVUS guidance vs. angiography guidance were then examined. Ten readily available clinical, laboratory, and angiographic variables were selected for inclusion in the TVF-ACS risk score. A cut-off value of 15.64 discriminated angiography-guided PCI patients at high-risk vs. low risk [area under the curve (AUC) 0.715, 95% confidence interval (CI) 0.653–0.777]. The AUC was similar in the validation group [0.709 (95% CI 0.630–0.788)]. High-risk patients exhibited a higher 1-year rate of TVF compared with low-risk patients [19.8 vs. 5.7%, hazard ratio (HR) 3.81, 95% CI 2.06–7.02, P = 0.00002]. Among 3486 randomized patients, IVUS guidance compared with angiography guidance reduced 1-year TVF in high-risk patients (6.9 vs. 17.6%; HR 0.38, 95% CI 0.24–0.59) with a lesser effect in low-risk patients (3.2 vs. 4.3%; HR 0.75, 95% CI 0.51–1.11; Pinteraction = 0.02). External validation in the IVUS-XPL and ULTIMATE trials confirmed these benefits but with consistent effects in high- and low-risk patients (Pinteractions = 0.49 and 0.92, respectively). Conclusion: The TVF-ACS risk score reliably stratifies ACS patients undergoing PCI into high- and low-risk groups. The benefits of IVUS guidance during PCI are most pronounced in high-risk ACS patients, although all ACS patients are likely to benefit.
- 28 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Open AccessIntravascular ultrasound–guided percutaneous coronary intervention in acute coronary syndrome stratified by the TVF-ACS risk score: the IVUS-ACS trial
Aims: The IVUS-ACS trial demonstrated that intravascular ultrasound (IVUS) guidance reduces target-vessel failure (TVF) in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Whether this benefit applies to all ACS patients across the spectrum of risk is unknown. We sought to develop a new risk score for 1-year TVF after PCI in ACS and determine whether IVUS guidance compared with angiography guidance improves outcomes in both high- and low-risk patients. Methods and results: From the angiography-guided group of the IVUS-ACS trial (n = 1743), the TVF-ACS risk score was developed using the least absolute shrinkage and selection operator method in a derivation group (n = 1288), and its robustness was assessed in an internal validation group (n = 455). External validation was then performed separately in the IVUS-XPL and ULTIMATE trials. Outcomes in high- and low-risk patients randomized to IVUS guidance vs. angiography guidance were then examined. Ten readily available clinical, laboratory, and angiographic variables were selected for inclusion in the TVF-ACS risk score. A cut-off value of 15.64 discriminated angiography-guided PCI patients at high-risk vs. low risk [area under the curve (AUC) 0.715, 95% confidence interval (CI) 0.653–0.777]. The AUC was similar in the validation group [0.709 (95% CI 0.630–0.788)]. High-risk patients exhibited a higher 1-year rate of TVF compared with low-risk patients [19.8 vs. 5.7%, hazard ratio (HR) 3.81, 95% CI 2.06–7.02, P = 0.00002]. Among 3486 randomized patients, IVUS guidance compared with angiography guidance reduced 1-year TVF in high-risk patients (6.9 vs. 17.6%; HR 0.38, 95% CI 0.24–0.59) with a lesser effect in low-risk patients (3.2 vs. 4.3%; HR 0.75, 95% CI 0.51–1.11; Pinteraction = 0.02). External validation in the IVUS-XPL and ULTIMATE trials confirmed these benefits but with consistent effects in high- and low-risk patients (Pinteractions = 0.49 and 0.92, respectively). Conclusion: The TVF-ACS risk score reliably stratifies ACS patients undergoing PCI into high- and low-risk groups. The benefits of IVUS guidance during PCI are most pronounced in high-risk ACS patients, although all ACS patients are likely to benefit.
- Open Access
Lung cancer risk assessment by prediction model: a global perspective
Background: Numerous lung cancer risk prediction models have been developed and validated worldwide. It is imperative to offer a comprehensive overview and comparative analysis of their performances. Methods: We conducted an extensive literature search to identify studies developing and/or validating lung cancer risk prediction models. Then we summarised and compared the external performance of these models, focusing on discriminative accuracy (C-index) and calibration performance (E:O ratio). Results: After an initial screening of 10 210 articles, 35 studies on 21 distinct prediction models were identified, which used 42 different types of predictors spanning seven categories. Notable performance variations were observed in external validations. In North American cohorts, the C-index ranged from 0.60 to 0.87, with E:O ratios from 0.62 to 3.70. Among the European cohorts, the Trøndelag health study HUNT and CanPredict exhibited C-indices surpassing 0.870. Conversely, the Bach, lung cancer risk assessment tool (LCRAT), prostate, lung, colorectal and ovarian cancer screening (PLCO) m2012 and PLCO all2014 performed poorly in electronic health records of the Qresearch database subgroup, with C-indices falling below 0.60. PLCO m2012 reached the best E:O ratio of 1.00 (95% CI: 0.93 to 1.08) in the UK Biobank subgroup. In Asian cohorts, the C-index ranged from 0.54 to 0.87. Only three models, Korean Men, LCRAT and Liverpool lung project incidence risk model (LLPi), achieved a C-index exceeding 0.80. LCRAT demonstrated the best calibration, while Hoggart performed the worst. Conclusions: Performance of lung cancer risk prediction models, despite being well developed and validated, varies in diverse populations. Significant regional imbalance persists in the development of these models. Rigorous external validation or recalibration study in the target population is crucial in accordance with the guidance prior to model implementation. PROSPERO registration number: CRD42022324602.
Open AccessLung cancer risk assessment by prediction model: a global perspective
Background: Numerous lung cancer risk prediction models have been developed and validated worldwide. It is imperative to offer a comprehensive overview and comparative analysis of their performances. Methods: We conducted an extensive literature search to identify studies developing and/or validating lung cancer risk prediction models. Then we summarised and compared the external performance of these models, focusing on discriminative accuracy (C-index) and calibration performance (E:O ratio). Results: After an initial screening of 10 210 articles, 35 studies on 21 distinct prediction models were identified, which used 42 different types of predictors spanning seven categories. Notable performance variations were observed in external validations. In North American cohorts, the C-index ranged from 0.60 to 0.87, with E:O ratios from 0.62 to 3.70. Among the European cohorts, the Trøndelag health study HUNT and CanPredict exhibited C-indices surpassing 0.870. Conversely, the Bach, lung cancer risk assessment tool (LCRAT), prostate, lung, colorectal and ovarian cancer screening (PLCO) m2012 and PLCO all2014 performed poorly in electronic health records of the Qresearch database subgroup, with C-indices falling below 0.60. PLCO m2012 reached the best E:O ratio of 1.00 (95% CI: 0.93 to 1.08) in the UK Biobank subgroup. In Asian cohorts, the C-index ranged from 0.54 to 0.87. Only three models, Korean Men, LCRAT and Liverpool lung project incidence risk model (LLPi), achieved a C-index exceeding 0.80. LCRAT demonstrated the best calibration, while Hoggart performed the worst. Conclusions: Performance of lung cancer risk prediction models, despite being well developed and validated, varies in diverse populations. Significant regional imbalance persists in the development of these models. Rigorous external validation or recalibration study in the target population is crucial in accordance with the guidance prior to model implementation. PROSPERO registration number: CRD42022324602.